Piperazine

Piperazine

SCHEMBL4823909

C1CNCCN1.NC(=O)Cl

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
HIF1A Q16665 1/20 0.43
PDE4A P27815 1/20 0.43
KDR P35968 1/20 0.43
KDM4E B2RXH2 3/20 0.37
KMT2A Q03164 2/20 0.37
CXCR4 P61073 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
TSHR P16473 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL3258524 0.97 MAPT (0.40) MAPTHIF1APDE4AKDRKDM4E
Pyrrolidine SCHEMBL3402069 0.87
Piperazine SCHEMBL1613092 0.85 MAPT (0.50) MAPTHIF1APDE4AKDRKDM4E
Piperazine SCHEMBL3987157 0.85 HIF1A (0.50) MAPTHIF1APDE4AKDRKDM4E
Piperazine SCHEMBL4778411 0.85 MAPT (0.50) MAPTHIF1APDE4AKDRKDM4E
Piperidine SCHEMBL4603677 0.84 ALDH1A1 (0.53) MAPTKDM4EKMT2ACXCR4SMN1; SMN2
Azepane SCHEMBL9671876 0.84 ALDH1A1 (0.53) MAPTKDM4EKMT2ACXCR4SMN1; SMN2
Piperazine SCHEMBL11443166 0.81 MAPT (0.46) MAPTHIF1APDE4AKDRKDM4E
Piperazine SCHEMBL250578 0.81 ACHE (0.54) MAPTHIF1APDE4AKDRKDM4E
Piperazine SCHEMBL3992732 0.81 HIF1A (0.46) MAPTHIF1APDE4AKDRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456173-B2 Compositions comprising zopiclone derivatives and methods of making and using the same SEPRACOR INC. (US) 2008-11-25 US disclosed
US-7189715-B2 Compositions comprising zopiclone derivatives and methods of making and using the same SEPRACOR INC. (US) 2007-03-13 US disclosed
US-20070049590-A1 Compositions comprising zopiclone derivatives and methods of making and using the same ALTER DOMUS (US) LLC 2007-03-01 US disclosed
US-20040147521-A1 Compositions comprising zopiclone derivatives and methods of making and using the same ALTER DOMUS (US) LLC 2004-07-29 US disclosed
WO-2004037212-A2 COMPOSITIONS COMPRISING ZOPICLONE DERIVATIVES AND METHODS OF MAKING AND USING THE SAME SEPRACOR, INC. (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049590-A1 Compositions comprising zopiclone derivatives and methods of making and using the same CYP51A1, CYP3A43, HSD17B7 MAPT 1700/4885HIF1A 3990/4885PDE4A 1089/4885
US-20040147521-A1 Compositions comprising zopiclone derivatives and methods of making and using the same CYP51A1, CYP3A43, CYP4A11 MAPT 1769/4885HIF1A 3694/4885PDE4A 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.